/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Xenon Pharmaceuticals Inc Share Price Today: Live Updates & Key Insights

Xenon Pharmaceuticals Inc share price today is $57.84, up -1.93%. The stock opened at $58.51 against the previous close of $59.04, with an intraday high of $59.26 and low of $56.95.

Xenon Pharmaceuticals Inc Share Price Chart

style
pb-0

Xenon Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Xenon Pharmaceuticals Inc Share Price Performance

$57.84 -0.0193(-1.93%) XENE at 13 Mar 2026 03:56 PM Biotechnology
Lowest Today 56.95
Highest Today 59.26
Today’s Open 58.51
Prev. Close 59.04
52 Week High 63.95
52 Week Low 26.74
Day’s Range: Low 56.95 High 59.26
52-Week Range: Low 26.74 High 63.95
1 day return -
1 Week return +38.17
1 month return +39.74
3 month return +32.82
6 month return +61.04
1 year return +64.84
3 year return +69.03
5 year return +190.27
10 year return -

Xenon Pharmaceuticals Inc Institutional Holdings

FMR Inc 10.72

venBio Select Advisor LLC 6.52

BlackRock Inc 5.74

Wellington Management Company LLP 5.73

Driehaus Capital Management LLC 5.46

American Funds SMALLCAP World A 4.87

HHG PLC 4.74

Vanguard Health Care Inv 4.02

Capital Research & Mgmt Co - Division 3 3.82

JPMorgan Chase & Co 3.36

Polar Capital Holdings PLC 3.06

Strategic Advisers Fidelity US TtlStk 2.42

iShares Russell 2000 ETF 2.21

BRAIDWELL LP 2.19

COMMODORE CAPITAL LP 2.16

AllianceBernstein L.P. 1.99

State Street Corp 1.76

Millennium Management LLC 1.66

Jennison Associates LLC 1.55

Fidelity Select Health Care 1.55

Holocene Advisors, LP 1.54

Affinity Asset Advisors, LLC 1.50

Westfield Capital Management Company, L.P. 1.47

Deep Track Capital, LP 1.44

Geode Capital Management, LLC 1.17

Polar Capital Healthcare Opports Inc 1.09

Polar Capital Biotech S Inc 0.90

Fidelity Small Cap Index 0.90

Fidelity Advisor Biotechnology I 0.85

Fidelity Advisor Health Care I 0.83

iShares Russell 2000 Growth ETF 0.76

BNP Paribas US Small Cap ClassicC 0.73

iShares Biotechnology ETF 0.67

Fidelity Stock Selector Small Cap 0.63

Jennison Health Sciences Equity 0.63

PGIM Jennison Health Sciences Z 0.63

American Century Small Cap Growth Inv 0.63

American Century U.S. Small Cap Growth 0.63

JPMorgan Small Cap Growth A 0.60

Fidelity Small Cap Growth 0.58

Xenon Pharmaceuticals Inc Market Status

Strong Buy: 14

Buy: 5

Hold: 0

Sell: 0

Strong Sell: 0

Xenon Pharmaceuticals Inc Fundamentals

Market Cap 4911.56 M

PB Ratio 8.4426

PE Ratio 0.0

Enterprise Value 4370.61 M

Total Assets 981.67 M

Volume 2870308

Xenon Pharmaceuticals Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:9434000 9.4M, FY21:18437000 18.4M, FY20:32166000 32.2M, FY19:6829000 6.8M

Annual Profit FY23:null 0.0M, FY22:9434000 9.4M, FY21:18437000 18.4M, FY20:32166000 32.2M, FY19:6829000 6.8M

Annual Net worth FY23:-175045000 -175.0M, FY22:-125373000 -125.4M, FY21:-78882000 -78.9M, FY20:-28837000 -28.8M, FY19:-41595000 -41.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:7500000 7.5M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-77054000 -77.1M, Q2/2025:-632000 -0.6M, Q1/2025:7500000 7.5M, Q3/2024:null 0.0M, Q2/2024:-659000 -0.7M

Quarterly Net worth Q3/2025:-90896000 -90.9M, Q2/2025:-84706000 -84.7M, Q1/2025:-65047000 -65.0M, Q3/2024:-62790000 -62.8M, Q2/2024:-57924000 -57.9M

About Xenon Pharmaceuticals Inc & investment objective

Company Information Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Organisation Biotechnology

Employees 358

Industry Biotechnology

CEO Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow